Literature DB >> 990177

An epidemiological study of the haemostatic and other effects of oral contraceptives.

T W Meade, M Brozović, R Chakrabarth, D J Howarth, W R North, Y Stirling.   

Abstract

Factors V, VII and VIII (each determined by biological assay), fibrinogen, platelet count and adhesiveness, and fibrinolytic activity were measured in 234 white pre-menopausal women, of whom 57 (24%) were on oral contraceptives and 177 (76%) were not. Cholesterol, triglyceride and blood pressure levels were also recorded. In 20 of the women on oral contraceptives, and in an age-matched group of 20 who were not, prothrombin, factor X, antithrombin III and alpha 2-macroglobulin levels were determined, and factors VII and VIII were also measured immunologically. For the majority of the variables studied, the differences between those using and not using oral contraceptives were greater in younger than older women; in the case of factor VII (biological assay) and fibrinogen, the differences between the regression slopes on age were statistically significant, and mean values were substantially higher in those on oral contraceptives. There was also a significant difference between regression slopes on age for cholesterol. Mean levels of prothrombin, factors VII (immunological assay) and X, triglycerides and blood pressure were significantly higher, and mean levels of antithrombin III significantly lower, in those on oral contraceptives compared with those not. Overall, fibrinolytic activity was significantly higher in the women on oral contraceptives; this difference was, however, almost entirely due to the greatly increased fibrinolytic activity of the non-smokers on oral contraceptives, activity in the smokers on oral contraceptives being similar to that of the women not on these preparations. There were no significant differences in mean platelet count or adhesiveness, or in haemoglobin, packed cell volume, uric acid and blood sugar levels. Among the women on oral contraceptives, there was a significant negative correlation between factor VIII and fibrinolytic activity; this was largely due to five women all of blood groups A and B, in whom, besides high factor-VIII levels and poor fibrinolytic activity, other variables (e.g. fibrinogen) were raised in a direction that might be expected to favour thrombogenesis. It is possible that it is those women whose fibrinolytic activity does not increase in order to compensate for the effects of oral contraceptives on clotting factors, lipids and blood pressure, who are at special risk of thromboembolic episodes. The differential effects of oral contraceptives by age must be borne in mind in evaluating the effects of these preparations on the haemostatic and lipid systems.

Entities:  

Keywords:  Acceptor Characteristics; Age Factors; Biology; Blood Coagulation Effects; Comparative Studies; Contraception; Contraceptive Methods--side effects; Demographic Factors; Economic Factors; Epidemiologic Methods; Family Planning; Hematological Effects; Hemic System; Marital Status; Nuptiality; Oral Contraceptives--side effects; Physiology; Population; Population Characteristics; Research Methodology; Socioeconomic Factors; Socioeconomic Status; Studies

Mesh:

Substances:

Year:  1976        PMID: 990177     DOI: 10.1111/j.1365-2141.1976.tb03582.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Risk factors for thromboembolism: pathophysiology and detection.

Authors:  S Solymoss
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

2.  A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

Authors:  Kevin R Viel; Deepa K Machiah; Diane M Warren; Manana Khachidze; Alfonso Buil; Karl Fernstrom; Juan C Souto; Juan M Peralta; Todd Smith; John Blangero; Sandra Porter; Stephen T Warren; Jordi Fontcuberta; Jose M Soria; W Dana Flanders; Laura Almasy; Tom E Howard
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

3.  [Determination of reference ranges of rheologic parameters: study of 653 randomly selected probands of the Aachen district].

Authors:  F Jung; H Kiesewetter; H G Roggenkamp; H P Nüttgens; E B Ringelstein; M Gerhards; G Kotitschke; E Wenzel; H Zeller
Journal:  Klin Wochenschr       Date:  1986-04-15

Review 4.  Mechanisms of deep vein thrombosis: a review.

Authors:  M Brozović
Journal:  J R Soc Med       Date:  1979-08       Impact factor: 5.344

Review 5.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

6.  Ethnic group comparisons of variables associated with ischaemic heart disease.

Authors:  T W Meade; M Brozović; R Chakrabarti; A P Haines; W R North; Y Stirling
Journal:  Br Heart J       Date:  1978-07

Review 7.  The third S.K. & F. Prize lecture, University of London, December 1981. The clinical pharmacology of oral contraceptive steroids.

Authors:  M L Orme
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

8.  The effect of low-dose estroprogestinic preparations on prothrombin complex factors: no significant increase after an 8-month trial.

Authors:  A Girolami; M Procidano; M Vicariotto; G Cappellato; T Vicari
Journal:  Blut       Date:  1985-03

9.  Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.

Authors:  P Quehenberger; S Kapiotis; C Pärtan; B Schneider; R Wenzel; A Gaiger; W Speiser
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

10.  Mesterolone: thrombosis during treatment, and a study of its prothrombotic effects.

Authors:  G D Lowe; J E Thomson; M M Reavey; C D Forbes; C R Prentice
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.